(e) MAPE up to 100 per cent allowed while fixing prices of such formulations under DPCO, 1987 against the mark up of 60 per cent allowed under DPCO, 1979.

Supplementary Report of the Kelkar Committee

1418. SHRI JAGESH DESAI: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 3724 given in the Rajya Sabha on the 29th August 1988 and state:

(a) whether it is a fact that Kelkar Committee has submitted its supplementary report to the Government;

(b) if so, when was the report submitted and what are the main contents of the Report;

(c) what were the total number of communications received from consumer, Medical Associations and Members of Parliament by Kelkar Committee;

(d) what are the details of issues raised these communications;

(e) what are the details of recommendations made on each of these issues; and

(f) by when Government would take decision on the Report and by when the Report would be laid on the Table of the House?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (f) A large number of representations were received against the recommendations of the Kelkar Committee, which were forwarded to the committee. The supplementary report recently submitted by the committee is under examination.

Price Decontrol on Drug

1419. SHRI JAGESH DESAI: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 3736 given in the Rajya Sabha on the 29th August, 1988 and state:

(a) whether it is a fact that the landed cost of imported Zinc Bacitracin, Polymixin-B-Sulphate, Flucinolone Acetonide and Triprolidine Hcl was more than Rs. 50 lakhs during the year 1985-86 and 1986-87 based on the information provided;

(b) whether it is also a fact that there is a monopoly production of formulations based on these drugs;

(c) if so, on what basis Kelkar Committee recommended these drugs for price decontrol;

(d) whether it is also a fact that Kelkar Committee did not use any data;

(e) whether it is also a fact that his Ministry did not cross check the facts; and

(f) if so, what steps have been taken to remove these anomalies and what are the details of revised recommendations of the committee?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (f) A large number of representations were received against the recommendations of Kelkar Committee, which were forwarded to the Committee. The supplementary report recently submitted by the Committee is under examination.

Commission on Sale of Baralgon Pheniramine Glybenclamide and Fursemide

1420 SHRI JAGESH DESAI: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 3631 given in the Rajya Sabha on the 29th August 1988 and state:

(a) whether it is a fact that none of four bulk drugs i.e. Baralgon Pheniramine, Glybenclamide Fursemide have been sold

(b) if so, what are the basis of arriving at net realisation;

(c) whether it is a fact that commision is part of MAPE;

(d) if so, how the commission has been deducted for arriving at net realisation; and

(e) what was the production of each of these drugs from the relevant date yearwise, prices charged by the company in formulations in respect of each bulk drug and what is the notified price of each?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (e) The required details to the extent available would be collected and laid on the Table of the House.

Court Cases regarding Vitamin Formulations

1421. SHRI JAGESH DESAI: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 3657 given in the Rajya Sabha on the 29th August, 1988 and state:

(a) whether it is a fact that his Ministry challenged the decision of Bombay High Court before the full bench of the court in respect of vitamin formulations;

(b) if so, what are the basis of information that his Ministry accepted the request of the company;

(c) what are the contents of the request filed by the company with Government;

(d) what were the prices of vitamin formulations as fixed by his Ministry under DPCO, 1979 and what were the prices which the company was charging under the court order;

(e) what are the prices which his Ministry has now fixed under DPCO, 1987 for each formulations; and

(f) what is the price of bulk drugs taken by his Ministry while fixing the price of vitamin formulations and what is the percentage increase in price of each formulations of this company?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) Yes Sir.

(b) and (c) In its letter dated the 6th April, 1988 M/s. Pfizer conveyed that upon receipt of revised prices under DPCO, 1987, with MAPE adjusted prices of its non-leader Vitamin and other formulations, the company shall withdraw the pending Court cases in respect of Vitamin formulations. Subsequently, the company filed an application for withdrawal of their Writ Petition in Bombay High Court.

(d) to (f) The revised prices were fixed under DPCO, 1987 by merely adjusting the rate of MAPE from 60 per cent to 100 per cent in the prices already fixed by the Government under DPCO, 1979 except in the case of Terramycin SF Capsules. The requried details to the extent available are given in the statement at Annexure. (*See* Appendix CXLVIII Annexure No. 62).

Prices of bulk drugs

1422. DR. BAPU KALDATE: Will the Minister of INDUSTRY be pleased to refer to the Answer to Unstarred Question 3752 given in the Rajya Sabha on the 29th August, 1988 and state:

(a) what is the total number of formulations based on Betamethasone its salts and Dexamethasone being marketed by the companies who challenged the Government fixed prices under DPCO, 1979;

(b) whether it is a fact that these companies have not implemented the fixed prices though upheld by courts;